Clinical Trial Available Supplemental Table 5. Available therapies and clinical trials Gene FDA Approved Therapy Off-label Therapy Clinical Trial Available ALK Crizotinib, Ceritinib, Alectinib - NCT01828112, NCT02201992 APC Celecoxib ARID1A NCT01897571, NCT02082977 BRAF Sorafenib, Regorafenib, Trametinib, Vemurafenib, Dabrafenib, Cobimetinib NCT01248247, NCT01306045, NCT01336634 CCNE1 CDK4 Palbociclib NCT02079636 CDK6 NCT02022982, NCT02308020 CDKN2A NCT02022982 CTNNB1 EGFR Afatinib, Erlotinib, Gefitinib, Osimertinib Lapatinib, Panitumumab, Gefitinib, Erlotinib, Afatinib, Necitumumab NCT01746251, NCT02108964, NCT02113813, NCT02143466, NCT02322281, NCT02438722, NCT02450591, NCT02588261 ERBB2 Lapatinib, Trasuzumab, ado-Trasuzumab Emtansine, Pertuzumab, Afatinib NCT01306045, NCT01920061 FBXW7 Temsirolimus, Everolimus NCT01920061 FGFR1 Pazopanib, Regorafenib, Ponatinib, Lenvatinib GNAS Trametinib, Cobimetinib NCT01449058, NCT01248247 IDH2 Azacitidine, Decitabine NCT00978250 KIT Pazopanib, Sorafenib, Sunitinib, Temsirolimus, Nilotinib, Axitinib, Regorafenib, Ponatinib, Lenvatinib, Dasatinib, Everolimus, Imatinib KRAS NCT01912625, NCT02070549, NCT02258607, NCT02258607, NCT01248247 MET Crizotinib MPL Ruxolitinib MYC NCT02214147, NCT02327169, NCT01471964 NF1 Temsirolimus, Trametinib, Everolimus, Cobimetinib NCT01920061, NCT01920061 PIK3CA NCT01248247, NCT01920061, NCT02079636 PTEN PTPN11 Trametinib NCT01306045 STK11 Temsirolimus, Bosutinib, Dasatinib, Everolimus TP53 NCT01924260, NCT02214147, NCT01677559, NCT02327169,NCT01471964, NCT02482311, NCT01827384, NCT02511795, NCT02261805